Trillium Announces Voting Results From the Annual General and Special Meeting of Shareholders

Rhea-AI Summary

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) announced the results from its Annual General and Special Meeting held on June 8, 2021. Notable outcomes included the re-election of Mr. Luke Beshar, Dr. Michael Kamarck, and others as directors, with Beshar receiving 89.6% of votes in favor. Ernst & Young LLP was reappointed as auditors. Shareholders approved an advisory vote on executive compensation, suggesting annual reviews. The company focuses on developing therapies targeting cancer, particularly through its CD47 programs, TTI-622 and TTI-621.

Positive

• High shareholder approval rates for director elections, with Dr. Kamarck receiving 99.7% support.
• Reappointment of Ernst & Young as auditors ensures continued financial oversight.
• Approval of annual advisory votes on executive compensation reflects shareholder engagement.

Negative

• Only 81.8% of votes in favor of Mr. Paul Walker indicates potential dissent among shareholders.

CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 8, 2021.

The results of the director elections were as follows:

Name	Votes in Favor	% Votes in Favor	Votes Withheld	% Votes Withheld
Mr. Luke Beshar	45,690,551	89.6	5,331,299	10.4
Dr. Michael Kamarck	50,875,937	99.7	145,912	0.3
Mr. Scott Myers	50,879,347	99.7	142,503	0.3
Mr. Paolo Pucci	50,842,785	99.7	179,065	0.3
Dr. Jan Skvarka	50,903,051	99.8	118,798	0.2
Dr. Helen Tayton-Martin	50,766,458	99.5	255,391	0.5
Mr. Paul Walker	41,737,821	81.8	9,284,029	18.2

The shareholders of the Corporation also voted to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants as auditors of the Corporation for the ensuing year. In addition, the shareholders approved the non-binding, advisory vote on the compensation paid to the Corporation’s named executive officers and recommended that future advisory votes on the compensation paid to the Corporation’s named executive officers should be held every year. For complete voting results on all matters approved at the Meeting, please see the Corporation’s Report of Voting Results dated June 9, 2021 available on SEDAR at www.sedar.com and the Current Report on Form 8-K filed on EDGAR.

About Trillium Therapeutics
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-622 and TTI-621, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.

For more information visit: www.trilliumtherapeutics.com 

Company Contact:
Rosemary Harrison
SVP, Corporate Development and Strategy
Trillium Therapeutics Inc.
416-595-0627 x225
investors@trilliumtherapeutics.com
www.trilliumtherapeutics.com  

Media Relations:
Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com

 

FAQ

What were the voting results for Trillium Therapeutics Inc. at the June 2021 meeting?

Trillium Therapeutics Inc. reported that Mr. Luke Beshar received 89.6% of votes in favor, while Dr. Michael Kamarck received 99.7%.

Who were re-elected as directors during the June 2021 meeting for TRIL?

Directors re-elected include Mr. Luke Beshar, Dr. Michael Kamarck, Mr. Scott Myers, and others.

What was the outcome of the advisory vote on executive compensation for TRIL?

Shareholders approved a non-binding advisory vote on executive compensation, recommending annual reviews.

Who was appointed as auditors for Trillium Therapeutics in 2021?

Ernst & Young LLP was reappointed as auditors for the upcoming year.

What is Trillium Therapeutics focusing on in their clinical programs?

Trillium Therapeutics is developing immunotherapies targeting CD47 to treat cancer.